Idasanutlin

Drug Profile

Idasanutlin

Alternative Names: RG 7388; RO 5503781

Latest Information Update: 06 Jun 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Mayo Clinic; National Cancer Institute (USA); NHS Greater Glasgow and Clyde; Roche; University of Glasgow
  • Class Aminobenzoic acids; Antineoplastics; Pyrrolidines; Small molecules
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase I/II Diffuse large B cell lymphoma; Follicular lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Prostate cancer
  • Phase I Cancer; Essential thrombocythaemia; Polycythaemia vera; Solid tumours

Most Recent Events

  • 06 Jun 2017 University Hospital Heidelberg plans a phase I/II trial in Glioblastoma (Newly diagnosed) in Germany (NCT03158389)
  • 01 May 2017 Phase-I/II clinical trials in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in New Zealand, USA (PO) after May 2017 (NCT03135262)
  • 01 May 2017 Phase-I/II clinical trials in Follicular lymphoma (Combination therapy, Second-line therapy or greater) in New Zealand, USA (PO) after May 2017 (NCT03135262)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top